Demographic Characteristics of Patients with Treatment Naïve Early and Established Rheumatoid Arthritis and Control Individuals with Osteoarthritis.

Values are the mean ± SD, unless otherwise stated. BMI, body mass index; DAS, disease activity score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; csDMARDs, conventional synthetic disease modifying antirheumatic drugs; bDMARDs, biologic disease modifying antirheumatic drugs; RFs, rheumatoid factors; anti-CCP, anti-cyclic citrullinated peptide; NA, not applicable. Types of bDMARDs: anti-TNFα (etanercept 3x, adalimumab 2x and golimumab 1x), anti-CD20 (rituximab 2x), anti-IL6R (tocilizumab 2x) and anti-IL17 (secukinumab 1x, open phase clinical trial). *p<0.05 for pairwise comparisons with ERA; ±p<0.001 for pairwise comparisons with ERA; §p<0.01 for pairwise comparisons with RA; ≠p<0.01 for pairwise comparisons with ERA; ***p<0.001 for pairwise comparisons with ERA wk 0; ǂp<0.001 for pairwise comparisons with ERA and RA Demographic Characteristics of Patients with Treatment Naïve Early and Established Rheumatoid Arthritis and Control Individuals with Osteoarthritis.